EDNRB and diabetic kidney disease: While atrasentan reduced proteinuria by 34% in diabetic nephropathy trials, its oncology applications are limited by fluid retention, potentially linked to EDNRB’s ceRNA regulatory network involving lncRNA FENDRR and miR-148a (40).